Role of tiotropium in the treatment of COPD

Kathryn L Rice, Ken M Kunisaki, Dennis E Niewoehner

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Tiotropium is a potent, long-acting, selective anticholinergic bronchodilator. Treatment with tiotropium produces sustained improvements in lung function, particularly FEV1 (peak, trough, average, and area under the curve) compared with either placebo or ipratropium in patients with moderate to severe COPD. Preliminary evidence suggests that treatment with tiotropium may slow the rate of decline in FEV1, but this finding awaits confirmation. Tiotropium reduces lung hyperinflation, with associated improvements in exercise capacity. Tiotropium, compared with either placebo or ipratropium, improves a variety of patient-centered outcomes, including subjective dyspnea ratings and HRQL scores. Tiotropium reduces the frequency of COPD exacerbations and of hospitalizations due to exacerbations, but has not been shown to reduce all-cause mortality. Compared with the long-acting bronchodilators, tiotropium provides incrementally better bronchodilation, but it is not clearly superior in terms of patient-centered outcomes. Tiotropium has a good safety profile; however patients with severe cardiac disease, bladder outlet obstruction, or narrow angle glaucoma were excluded from all studies. Medico economic analyses suggest that treatment with tiotropium may also be cost-effective, primarily by reducing costs associated with hospitalizations.

Original languageEnglish (US)
Pages (from-to)95-105
Number of pages11
JournalInternational Journal of COPD
Volume2
Issue number2
StatePublished - Aug 9 2007

Keywords

  • Anticholinergic bronchodilator
  • Chronic pulmonary disease
  • Tiotropium

Fingerprint

Dive into the research topics of 'Role of tiotropium in the treatment of COPD'. Together they form a unique fingerprint.

Cite this